Velpaclear is a fixed-dose combination of two antiviral agents that block replication of the hepatitis C virus by targeting key viral enzymes — NS5B polymerase (Sofosbuvir) and NS5A protein (Velpatasvir).
It is recommended for patients with genotypes 1 through 6, including those with compensated cirrhosis or HIV co-infection.
Recommended for:
All-genotype Hepatitis C patients
Interferon-intolerant or non-responding cases
Interferon-free first-line treatment
Retreatment after failed previous therapy
Chronic Hepatitis C infection (genotypes 1–6)
Patients with compensated liver cirrhosis
Previously treated or treatment-naive patients
One tablet is taken orally once daily, with or without food. Treatment duration is typically 12 weeks, depending on the patient's viral genotype and liver condition.
Contraindications:
Hypersensitivity to any component
Pregnancy and lactation (without medical advice)
Paediatric patients
Use with strong P-glycoprotein inducers (e.g., rifampin)
Side Effects:
Headache
Fatigue
Nausea
Sleep disturbances
Mild elevation of liver enzymes (rare)
